

ESMO 2018 Congress

Munich, Germany
October 19-23, 2018

Session Type:	Proffered Paper Session
Session Title:	Head and Neck Cancer
Presentation Number:	1044O
Presentation Date:	Monday, October 22, 2018
Presentation Time:	2:45 p.m. – 3:00 p.m. CEST
Presentation Title:	A phase 1b/2 study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results